Skip to main content

Table 3 Multivariate Cox analysis for OS and CSS among PSM population

From: A population-based predictive model to identify patients with signet ring cell carcinoma of the stomach who are most suitable for primary tumor resection

 

CSS

OS

Adjust HR (95% CI)

p value

Adjust HR (95% CI)

p value

Age

 < 50

Reference

   

 50–59

1.09 (0.94~1.25)

0.247

1.13 (0.99~1.3)

0.072

 60–69

1.21 (1.05~1.39)

0.007

1.29 (1.13~1.48)

< 0.001

 70–79

1.35 (1.16~1.55)

< 0.001

1.54 (1.35~1.77)

< 0.001

 > 80

1.81 (1.55~2.11)

< 0.001

2.17 (1.87~2.5)

< 0.001

Gender

 Female

Reference

   

 Male

1.06 (0.97~1.16)

0.203

1.06 (0.97~1.15)

0.174

Race

 Black

Reference

   

 White

0.93 (0.81~1.06)

0.275

0.88 (0.78~0.99)

0.04

 Other

0.73 (0.62~0.87)

< 0.001

0.68 (0.58~0.8)

< 0.001

Primary site

 Cardia, NOS

Reference

   

 Fundus of stomach

1.15 (0.89~1.49)

0.294

1.04 (0.82~1.32)

0.747

 Body of stomach

1.07 (0.9~1.27)

0.463

0.97 (0.83~1.14)

0.732

 Gastric antrum

1.07 (0.93~1.23)

0.354

1.01 (0.89~1.15)

0.851

 Pylorus

1.06 (0.8~1.4)

0.688

1.02 (0.79~1.32)

0.889

 Lesser curvature of stomach, NOS

0.92 (0.75~1.12)

0.385

0.88 (0.73~1.05)

0.156

 Greater curvature of stomach, NOS

1.02 (0.8~1.3)

0.862

0.96 (0.77~1.2)

0.731

 Overlapping lesion of stomach

1.24 (1.04~1.46)

0.014

1.18 (1.01~1.38)

0.041

 Stomach, NOS

1.33 (1.14~1.54)

< 0.001

1.24 (1.08~1.43)

0.002

Summary stage

 Unknown/unstaged

Reference

   

 Distant

3.04 (1.85~4.99)

< 0.001

2.46 (1.53~3.93)

< 0.001

 Localized

1.42 (0.93~2.17)

0.109

1.4 (0.95~2.06)

0.094

 Regional

2.29 (1.52~3.45)

< 0.001

1.95 (1.33~2.85)

0.001

AJCC stage group

 Unknown stage

Reference

   

 IA

0.59 (0.39~0.88)

0.009

0.65 (0.45~0.93)

0.019

 IB

0.82 (0.59~1.16)

0.267

0.84 (0.61~1.16)

0.295

 II

0.66 (0.46~0.94)

0.021

0.7 (0.5~0.97)

0.034

 IIIA

0.73 (0.51~1.05)

0.087

0.78 (0.56~1.09)

0.145

 IIIB

1.27 (0.71~2.28)

0.425

1.2 (0.67~2.13)

0.536

 IV

0.83 (0.58~1.2)

0.326

0.88 (0.62~1.24)

0.466

T stage

 T0

Reference

   

 T1

0.56 (0.08~4.02)

0.56

0.55 (0.08~3.96)

0.551

 T2a

0.62 (0.09~4.48)

0.635

0.62 (0.09~4.49)

0.638

 T2b

0.78 (0.11~5.6)

0.805

0.74 (0.1~5.32)

0.765

 T2NOS

0.44 (0.06~3.42)

0.43

0.42 (0.06~3.28)

0.412

 T3

0.82 (0.11~5.88)

0.842

0.79 (0.11~5.7)

0.818

 T4

0.9 (0.13~6.45)

0.915

0.85 (0.12~6.12)

0.875

 TX

0.83 (0.11~5.99)

0.852

0.8 (0.11~5.75)

0.82

N stage

 N0

Reference

   

 N1

1.09 (0.96~1.23)

0.173

1.06 (0.95~1.2)

0.307

 N2

1.01 (0.83~1.24)

0.896

1.02 (0.84~1.24)

0.866

 N3

1.33 (1.04~1.71)

0.025

1.34 (1.05~1.7)

0.017

 NX

1.1 (0.9~1.35)

0.363

1.1 (0.91~1.34)

0.333

M stage

 M0

Reference

   

 M1

1.28 (0.92~1.77)

0.139

1.31 (0.95~1.79)

0.097

 MX

0.94 (0.69~1.29)

0.716

1.02 (0.77~1.35)

0.892

Radiation

 No

Reference

   

 Yes

0.9 (0.79~1.02)

0.087

0.89 (0.79~1)

0.041

Chemotherapy

 No

Reference

   

 Yes

0.71 (0.63~0.81)

< 0.001

0.71 (0.63~0.8)

< 0.001

Systemic surgery

 No

Reference

   

 Yes

0.75 (0.64~0.87)

< 0.001

0.76 (0.66~0.88)

< 0.001

Marital

 No

Reference

   

 Yes

0.91 (0.81~1.01)

0.089

0.88 (0.8~0.98)

0.017

Surgery to primary site

 No

Reference

   

 Yes

0.35 (0.32~0.38)

<0.001

0.36 (0.33~0.39)

<0.001